A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
Q2
A randomized controlled trial is conducted investigating the effects of different diagnostic imaging modalities on breast cancer mortality. 8,000 women are randomized to receive either conventional mammography or conventional mammography with breast MRI. The primary outcome is survival from the time of breast cancer diagnosis. The conventional mammography group has a median survival after diagnosis of 17.0 years. The MRI plus conventional mammography group has a median survival of 19.5 years. If this difference is statistically significant, which form of bias may be affecting the results?
Q3
A 55-year-old man presents for physical and preventive health screening, specifically for prostate cancer. He has not been to the doctor in a long time. Past medical history is significant for hypertension that is well-managed. Current medication is hydrochlorothiazide. He has one uncle who died of prostate cancer. He drinks one or two alcoholic drinks on the weekends and does not smoke. Today his temperature is 37.0°C (98.6°F), blood pressure is 125/75 mm Hg, pulse is 82/min, respiratory rate is 15/min, and oxygen saturation is 99% on room air. There are no significant findings on physical examination. Which of the following would be the most appropriate recommendation for prostate cancer screening in this patient?
Q4
Study X examined the relationship between coffee consumption and lung cancer. The authors of Study X retrospectively reviewed patients' reported coffee consumption and found that drinking greater than 6 cups of coffee per day was associated with an increased risk of developing lung cancer. However, Study X was criticized by the authors of Study Y. Study Y showed that increased coffee consumption was associated with smoking. What type of bias affected Study X, and what study design is geared to reduce the chance of that bias?
Q5
A research study is comparing 2 novel tests for the diagnosis of Alzheimer’s disease (AD). The first is a serum blood test, and the second is a novel PET radiotracer that binds to beta-amyloid plaques. The researchers intend to have one group of patients with AD assessed via the novel blood test, and the other group assessed via the novel PET examination. In comparing these 2 trial subsets, the authors of the study may encounter which type of bias?
Q6
A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?
Q7
A 46-year-old woman presents to her primary care physician for her annual examination. At her prior exam one year earlier, she had a Pap smear which was within normal limits. Which of the following health screenings is recommended for this patient?
Q8
A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?
Q9
A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?
Q10
A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?
Limitations and controversies in screening US Medical PG Practice Questions and MCQs
Question 1: A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
A. Late-look bias
B. Latency period (Correct Answer)
C. Confounding
D. Effect modification
E. Pygmalion effect
Explanation: ***Latency period***
- **Lung cancer** typically has a **long latency period**, often **20-30+ years**, between initial exposure to tobacco carcinogens and the development of clinically detectable disease.
- A **five-year study duration** in young smokers (ages 20-30) is **far too short** to observe the development of lung cancer, which explains the false negative finding.
- This represents a **fundamental flaw in study design** rather than a bias—the biological timeline of disease development was not adequately considered.
*Late-look bias*
- **Late-look bias** occurs when a study enrolls participants who have already survived the early high-risk period of a disease, leading to **underestimation of true mortality or incidence**.
- Also called **survival bias**, it involves studying a population that has already been "selected" by survival.
- This is not applicable here, as the study simply ended before sufficient time elapsed for disease to develop.
*Confounding*
- **Confounding** occurs when a third variable is associated with both the exposure and outcome, distorting the apparent relationship between them.
- While confounding can affect study results, it would not completely eliminate the detection of a strong, well-established association like smoking and lung cancer in a properly conducted prospective cohort study.
- The issue here is temporal (insufficient follow-up time), not the presence of an unmeasured confounder.
*Effect modification*
- **Effect modification** (also called interaction) occurs when the magnitude of an association between exposure and outcome differs across levels of a third variable.
- This represents a **true biological phenomenon**, not a study design flaw or bias.
- It would not explain the complete failure to detect any association.
*Pygmalion effect*
- The **Pygmalion effect** (observer-expectancy effect) refers to a psychological phenomenon where higher expectations lead to improved performance in the observed subjects.
- This concept is relevant to **behavioral and educational research**, not to objective epidemiological studies of disease incidence.
- It has no relevance to the biological relationship between carcinogen exposure and cancer development.
Question 2: A randomized controlled trial is conducted investigating the effects of different diagnostic imaging modalities on breast cancer mortality. 8,000 women are randomized to receive either conventional mammography or conventional mammography with breast MRI. The primary outcome is survival from the time of breast cancer diagnosis. The conventional mammography group has a median survival after diagnosis of 17.0 years. The MRI plus conventional mammography group has a median survival of 19.5 years. If this difference is statistically significant, which form of bias may be affecting the results?
A. Recall bias
B. Selection bias
C. Misclassification bias
D. Because this study is a randomized controlled trial, it is free of bias
E. Lead-time bias (Correct Answer)
Explanation: ***Lead-time bias***
- This bias occurs when a screening test diagnoses a disease earlier, making **survival appear longer** even if the actual time of death is unchanged.
- In this scenario, adding **MRI** may detect breast cancer at an earlier, asymptomatic stage, artificially extending the apparent survival duration from diagnosis without necessarily changing the ultimate prognosis.
*Recall bias*
- **Recall bias** applies to retrospective studies where subjects are asked to recall past exposures, and those with the outcome are more likely to remember potential exposures.
- It's irrelevant here as this is a **prospective randomized controlled trial** studying objective survival outcomes, not subjective past recollections.
*Selection bias*
- **Selection bias** occurs when participants are not randomly assigned to groups, leading to systematic differences between the groups influencing the outcome.
- This study is a **randomized controlled trial**, which is designed to minimize selection bias by ensuring participants have an equal chance of being assigned to either treatment arm.
*Misclassification bias*
- **Misclassification bias** happens when either the exposure or the outcome is incorrectly categorized, leading to erroneous associations.
- This study uses objective diagnostic imaging and survival data, thus reducing the likelihood of **misclassification of diagnosis or survival status**.
*Because this study is a randomized controlled trial, it is free of bias*
- While **randomized controlled trials (RCTs)** are considered the **gold standard** for minimizing bias, they are not entirely immune to all forms of bias.
- **Lead-time bias**, for instance, can still occur in RCTs involving screening or early diagnosis, as seen in this example, and other biases like **information bias** or **reporting bias** can also arise.
Question 3: A 55-year-old man presents for physical and preventive health screening, specifically for prostate cancer. He has not been to the doctor in a long time. Past medical history is significant for hypertension that is well-managed. Current medication is hydrochlorothiazide. He has one uncle who died of prostate cancer. He drinks one or two alcoholic drinks on the weekends and does not smoke. Today his temperature is 37.0°C (98.6°F), blood pressure is 125/75 mm Hg, pulse is 82/min, respiratory rate is 15/min, and oxygen saturation is 99% on room air. There are no significant findings on physical examination. Which of the following would be the most appropriate recommendation for prostate cancer screening in this patient?
A. Contrast CT of the abdomen and pelvis
B. Serum PSA level (Correct Answer)
C. Digital rectal examination
D. No screening indicated at this time
E. Transrectal ultrasound (TRUS)
Explanation: ***Serum PSA level***
- This patient is 55 years old and has a family history of prostate cancer (uncle), placing him at **average to increased risk** for prostate cancer.
- **Serum PSA (prostate-specific antigen) testing** is the primary screening tool for prostate cancer, often combined with shared decision-making with the patient.
*Contrast CT of the abdomen and pelvis*
- A CT scan is not a primary screening tool for prostate cancer but is used for **staging** once cancer is diagnosed or to investigate specific symptoms.
- It involves **radiation exposure** and **contrast dye risks** which are not justified for routine screening in an asymptomatic patient.
*Digital rectal examination*
- While DRE can detect prostate abnormalities, it has a **lower sensitivity and specificity** as a stand-alone screening test compared to PSA.
- Current guidelines often recommend DRE in conjunction with PSA, but **PSA remains the initial and most important screening test**.
*No screening indicated at this time*
- The patient's age (55) and family history (uncle with prostate cancer) warrant discussion about prostate cancer screening.
- The **American Cancer Society (ACS)** recommends starting discussions about screening at age 50 for average-risk men, and earlier for those with risk factors.
*Transrectal ultrasound (TRUS)*
- TRUS is not a screening test but is typically used to **guide prostate biopsies** if PSA levels are elevated or a DRE is abnormal.
- It is an **invasive procedure** and not appropriate for initial prostate cancer screening in asymptomatic individuals.
Question 4: Study X examined the relationship between coffee consumption and lung cancer. The authors of Study X retrospectively reviewed patients' reported coffee consumption and found that drinking greater than 6 cups of coffee per day was associated with an increased risk of developing lung cancer. However, Study X was criticized by the authors of Study Y. Study Y showed that increased coffee consumption was associated with smoking. What type of bias affected Study X, and what study design is geared to reduce the chance of that bias?
A. Observer bias; double blind analysis
B. Selection bias; randomization
C. Lead time bias; placebo
D. Measurement bias; blinding
E. Confounding; randomization (Correct Answer)
Explanation: ***Confounding; randomization***
- Study Y suggests that **smoking** is a **confounding variable** because it is associated with both increased coffee consumption (exposure) and increased risk of lung cancer (outcome), distorting the apparent relationship between coffee and lung cancer.
- **Randomization** in experimental studies (such as randomized controlled trials) helps reduce confounding by ensuring that known and unknown confounding factors are evenly distributed among study groups.
- In observational studies where randomization is not possible, confounding can be addressed through **stratification**, **matching**, or **multivariable adjustment** during analysis.
*Observer bias; double blind analysis*
- **Observer bias** occurs when researchers' beliefs or expectations influence the study outcome, which is not the primary issue described here regarding the relationship between coffee, smoking, and lung cancer.
- **Double-blind analysis** is a method to mitigate observer bias by ensuring neither participants nor researchers know who is in the control or experimental groups.
*Selection bias; randomization*
- **Selection bias** happens when the study population is not representative of the target population, leading to inaccurate results, which is not directly indicated by the interaction between coffee and smoking.
- While **randomization** is used to reduce selection bias by creating comparable groups, the core problem identified in Study X is confounding, not flawed participant selection.
*Lead time bias; placebo*
- **Lead time bias** occurs in screening programs when early detection without improved outcomes makes survival appear longer, an issue unrelated to the described association between coffee, smoking, and lung cancer.
- A **placebo** is an inactive treatment used in clinical trials to control for psychological effects, and its relevance here is limited to treatment intervention studies.
*Measurement bias; blinding*
- **Measurement bias** arises from systematic errors in data collection, such as inaccurate patient reporting of coffee consumption, but the main criticism from Study Y points to a third variable (smoking) affecting the association, not just flawed measurement.
- **Blinding** helps reduce measurement bias by preventing participants or researchers from knowing group assignments, thus minimizing conscious or unconscious influences on data collection.
Question 5: A research study is comparing 2 novel tests for the diagnosis of Alzheimer’s disease (AD). The first is a serum blood test, and the second is a novel PET radiotracer that binds to beta-amyloid plaques. The researchers intend to have one group of patients with AD assessed via the novel blood test, and the other group assessed via the novel PET examination. In comparing these 2 trial subsets, the authors of the study may encounter which type of bias?
A. Selection bias (Correct Answer)
B. Confounding bias
C. Recall bias
D. Measurement bias
E. Lead-time bias
Explanation: ***Selection bias***
- This occurs when different patient groups are assigned to different interventions or measurements in a way that creates **systematic differences** between comparison groups.
- In this study, having **separate patient groups** assessed with different diagnostic methods (blood test vs. PET scan) means any differences observed could be due to **differences in the patient populations** rather than differences in test performance.
- To validly compare two diagnostic tests, both tests should ideally be performed on the **same patients** (paired design) or patients should be **randomly assigned** to receive one test or the other, ensuring comparable groups.
- This is a fundamental **study design flaw** that prevents valid comparison of the two diagnostic methods.
*Measurement bias*
- Also called information bias, this occurs when there are systematic errors in how outcomes or exposures are measured.
- While using different measurement tools could introduce measurement variability, the primary issue here is that **different patient populations** are being compared, not just different measurement methods on the same population.
- Measurement bias would be more relevant if the same patients were assessed with both methods but one method was systematically misapplied or measured incorrectly.
*Confounding bias*
- This occurs when an extraneous variable is associated with both the exposure and outcome, distorting the observed relationship.
- While patient characteristics could confound results, the fundamental problem is the **study design itself** (separate groups for separate tests), which is selection bias.
*Recall bias*
- This involves systematic differences in how participants remember or report past events, common in **retrospective case-control studies**.
- Not relevant here, as this involves prospective diagnostic testing, not recollection of past exposures.
*Lead-time bias*
- Occurs in screening studies when earlier detection makes survival appear longer without changing disease outcomes.
- Not applicable to this scenario, which focuses on comparing two diagnostic methods in separate patient groups, not on survival or disease progression timing.
Question 6: A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?
A. Tertiary prevention
B. Primary prevention
C. Secondary prevention (Correct Answer)
D. Cancer screening does not fit into these categories
E. Quaternary prevention
Explanation: ***Secondary prevention***
- **Secondary prevention** aims to detect and treat a disease early, before symptoms appear, to prevent its progression or recurrence.
- **Cancer screening tests** such as mammograms, colonoscopies, and Pap smears fit this category perfectly as they are performed in asymptomatic individuals to identify early-stage cancer or pre-cancerous lesions.
*Tertiary prevention*
- **Tertiary prevention** focuses on minimizing the impact of an established disease and improving quality of life through treatment and rehabilitation.
- This would involve managing existing cancer, not screening for it.
*Primary prevention*
- **Primary prevention** aims to prevent a disease from occurring in the first place, often through health promotion and risk reduction.
- Examples include vaccination, lifestyle modifications (e.g., healthy diet, exercise), or avoiding smoking.
*Cancer screening does not fit into these categories*
- This statement is incorrect as cancer screening is a well-established component of preventive healthcare.
- It clearly falls within the defined categories of prevention, specifically secondary prevention.
*Quaternary prevention*
- **Quaternary prevention** aims to protect patients from medical interventions that are likely to cause more harm than good, or to avoid over-medicalization.
- This concept is distinct from screening for diseases and focuses on ethical considerations in medical care.
Question 7: A 46-year-old woman presents to her primary care physician for her annual examination. At her prior exam one year earlier, she had a Pap smear which was within normal limits. Which of the following health screenings is recommended for this patient?
A. Colorectal screening (Correct Answer)
B. Blood glucose and/or HbA1c screening
C. Blood pressure at least once every 3 years
D. Yearly Pap smear
E. Bone mineral density screening
Explanation: ***Colorectal screening***
- **Colorectal cancer screening** is generally recommended to start at age **45 years** for individuals at average risk.
- This patient is 46 years old, making immediate colorectal screening appropriate based on current guidelines.
*Blood glucose and/or HbA1c screening*
- **Blood glucose or HbA1c screening** for diabetes is recommended starting at age **35 for all adults** or earlier if there are risk factors such as obesity or a family history of diabetes.
- While this patient is 46, this screening should have already been initiated, and it is not the *most* uniquely recommended screening for this specific age that might have been overlooked.
*Blood pressure at least once every 3 years*
- **Blood pressure screening** should be performed **at least annually** for adults aged 40 and older, or more frequently if there are risk factors.
- Screening only every 3 years is insufficient for a 46-year-old patient.
*Yearly Pap smear*
- **Pap smear frequency** has changed; for women aged 30-65 with normal results, screening is recommended every **3 years** with cytology alone, or every 5 years with high-risk HPV testing alone or co-testing.
- A yearly Pap smear is no longer typical practice for a woman with normal prior results and no specific risk factors.
*Bone mineral density screening*
- **Bone mineral density (BMD) screening** for osteoporosis is typically recommended for women starting at age **65 years** or earlier if they have significant risk factors.
- This patient is 46 years old and has no mentioned risk factors, so BMD screening is not routinely indicated at this age.
Question 8: A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?
A. Perform 3-hour oral glucose tolerance test at 16 weeks
B. Diagnose gestational diabetes based on random glucose and begin treatment
C. Perform 1-hour glucose challenge test now
D. Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes (Correct Answer)
E. Defer screening until 24-28 weeks gestation per routine protocol
Explanation: ***Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes***
- A **BMI ≥ 30 kg/m²** is a major risk factor necessitating early screening at the first prenatal visit to identify **pre-existing (overture) diabetes**.
- Identifying hyperglycemia early in pregnancy allows for immediate management to reduce the risk of **congenital anomalies** associated with pre-gestational diabetes.
*Perform 1-hour glucose challenge test now*
- While the **1-hour GCT** is a valid tool for early screening, standard biomarkers like **fasting plasma glucose** or **HbA1c** are also appropriate for detecting overt diabetes at the initial visit.
- The goal in the first trimester for high-risk patients is often to rule out **Type 2 Diabetes mellitus** that existed prior to pregnancy.
*Defer screening until 24-28 weeks gestation per routine protocol*
- Routine screening at **24-28 weeks** is reserved for women without significant risk factors; this patient's **obesity** mandates earlier evaluation.
- Delayed screening in obese patients may miss a window for intensive **glycemic control** during critical fetal organogenesis.
*Diagnose gestational diabetes based on random glucose and begin treatment*
- A **random glucose of 118 mg/dL** is within the normal range and is not diagnostic of either GDM (which requires >200 mg/dL with symptoms) or overt diabetes.
- Diagnosis requires structured testing such as an **HbA1c ≥ 6.5%**, fasting glucose ≥ 126 mg/dL, or a formal **oral glucose tolerance test (OGTT)**.
*Perform 3-hour oral glucose tolerance test at 16 weeks*
- The **3-hour OGTT** is typically the second step of a two-step screening process and is not indicated as an initial screening tool at 16 weeks.
- High-risk patients should be screened as soon as possible, often at the **first prenatal visit** (12 weeks in this case), rather than waiting until the second trimester.
Question 9: A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?
A. Annual fecal immunochemical testing
B. Repeat colonoscopy in 3 years
C. Repeat colonoscopy in 10 years
D. Repeat colonoscopy in 1 year
E. Repeat colonoscopy in 5-10 years (Correct Answer)
Explanation: ***Repeat colonoscopy in 5-10 years***
- According to the **USMSTF 2020 guidelines**, patients with **1 to 2 small (<10 mm) tubular adenomas** should have a surveillance colonoscopy in **7-10 years**; however, for a single adenoma **≥ 10 mm** (like this 1.2 cm lesion) with low-grade dysplasia, the recommended interval is **5-10 years**.
- This recommendation balances the slightly higher risk of a **larger lesion** against the **low-grade pathology** and the patient's age and overall risk profile.
*Repeat colonoscopy in 10 years*
- A strictly **10-year interval** is reserved for patients with a **normal colonoscopy** or those with only **distal hyperplastic polyps**.
- While 10 years is the upper limit of the recommended range, the presence of a **1.2 cm adenoma** requires a surveillance designation rather than a standard screening interval.
*Repeat colonoscopy in 3 years*
- The **3-year interval** is indicated for **high-risk findings** such as **≥3 adenomas**, adenomas with **villous histology**, or those with **high-grade dysplasia**.
- This patient only had a single lesion with **low-grade dysplasia**, making 3-year surveillance an over-utilization of resources.
*Repeat colonoscopy in 1 year*
- A **1-year interval** is generally only indicated for cases of **incomplete resection**, piece-meal removal of large sessile polyps, or **inadequate bowel preparation**.
- It is not appropriate for a **completely removed** 1.2 cm tubular adenoma.
*Annual fecal immunochemical testing*
- **Fecal immunochemical testing (FIT)** is a primary **screening modality**, not a surveillance tool for patients who have already been diagnosed with adenomas via colonoscopy.
- Once an adenoma is identified, the patient enters a **colonoscopy-based surveillance** program to directly monitor for recurrent or advancing lesions.
Question 10: A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?
A. Begin mammography at age 35 and annually thereafter
B. Recommend clinical breast exam every 6 months only
C. Begin annual mammography now
D. Refer for genetic counseling and consider expanded testing with breast MRI screening (Correct Answer)
E. Reassure that negative BRCA testing indicates average risk
Explanation: ***Refer for genetic counseling and consider expanded testing with breast MRI screening***
- Despite a negative **BRCA1/2** result, the patient's pedigree shows a **high-risk family history** (early-onset breast and ovarian cancer), which may indicate other **high-penetrance mutations** like **PALB2, TP53, or PTEN**.
- Women with a **lifetime risk >20%** based on models (e.g., **Tyrer-Cuzick**) or those with hereditary risk require **supplemental screening with Breast MRI** in addition to mammography.
*Begin annual mammography now*
- **Annual mammography alone** is insufficient for patients with a significant hereditary risk profile; **Breast MRI** is required to improve sensitivity in high-risk populations.
- Screening usually begins at age 30 or **10 years earlier** than the youngest diagnosis in the family, but current guidelines prioritize comprehensive **risk assessment** first.
*Reassure that negative BRCA testing indicates average risk*
- A negative test in the patient (without a known familial mutation) is **uninformative**; it does not rule out other genetic drivers or a strong **polygenic risk**.
- Reassuring her as "average risk" ignores the significant **familial clustering** of cancer, potentially delaying lifesaving early detection measures.
*Recommend clinical breast exam every 6 months only*
- **Clinical breast exams** lack the sensitivity to serve as a standalone management strategy for women with high **familial risk**.
- Evidence suggests that clinical exams do not significantly reduce **mortality** compared to advanced imaging protocols in hereditary cancer syndromes.
*Begin mammography at age 35 and annually thereafter*
- This delay is inappropriate; for high-risk families, screening often starts at **age 25 to 30** depending on the specific history and risk models.
- Starting at age 35 without incorporating **MRI screening** or updated **multi-gene panel testing** fails to address her specific hereditary risk profile.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
